Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Mania (Lithium - adults - Mania)

Records returned : 11 (on 16 Jul 2025 at 22:58:06). Return to search results for ' Mania '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Blue
Formulations :
  • Not Specified
Restrictions / Comments:

Important

To be initiated by a specialist.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the Blue information sheet and other resources that were in place prior to the launch of the joint formulary.

Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Reserve for patients who are unable to swallow tablets.

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Oro-dispersible tablets are more cost effectice than oral solution. Reserve oral solution for use in patients where the required dose is not available in an oro-dispersible form.

 
Links :
R
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Off-label use.

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
Restrictions / Comments:

Important

Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Capsules are an unlicensed product.

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube

 
Links :
R
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
Indication :
Status :
Red
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.

 
Links :
R
SPC